Home / Business and Economy / Life Science Stocks Rebound: Danaher, Agilent Lead the Charge
Life Science Stocks Rebound: Danaher, Agilent Lead the Charge
3 Dec
Summary
- Agilent Technologies stock has risen approximately 50% from its April lows.
- Danaher shares have climbed 30% from their April lows since September.
- Morgan Stanley initiated coverage with a buy rating and a $270 price target.
The life sciences stock sector is demonstrating a robust recovery, signaling better prospects ahead for companies like Danaher. Agilent Technologies, a key player, exemplifies this turnaround, with its stock price climbing approximately 50% from its April lows. This industry-wide resurgence suggests a positive shift after a challenging post-pandemic period.
Companies that supply tools and technologies to pharmaceutical and biotech firms, often termed 'arms dealers' of the life science industry, are now seeing renewed interest. Danaher, along with peers like Thermo Fisher, Revvity, and Waters, is benefiting from this trend. After a period of over-ordering and subsequent demand contraction, the industry is normalizing.
Danaher's stock has shown significant gains, rising 30% from its April lows, largely since late September. Wall Street's enthusiasm has been reignited by strong quarterly results and guidance. Analysts at Morgan Stanley initiated coverage with a buy-equivalent rating, projecting mid-single-digit revenue growth for Danaher into 2026, and assigned a $270 price target.
